U.S. Life Sciences Stock News

Oruka Therapeutics (ORKA) stock is drawing fresh attention after positive interim Phase 2a data for lead antibody ORKA-001 in moderate to severe plaque psoriasis, as well as an expanded IL-23 license that now clearly covers inflammatory bowel disease. See our latest analysis for Oruka Therapeutics. The latest data and licensing news come after a sharp move in the share price, with a 1-day share price return of 8.88% and a 7-day share price return of 7.42%. However, the 30-day share price...

Flex (NasdaqGS:FLEX) has completed its acquisition of Electrical Power Products (EP²). The company has also finalized plans to separate its Power and Cloud business into a new entity, often referred to as SpinCo. These moves expand Flex's reach in grid modernization, customized power control, utility markets, and AI data center infrastructure. The EP² deal is described as accretive to earnings, and the related credit agreement is now closed. For investors watching electrification and AI...

Recent performance context Clover Health Investments (CLOV) has drawn attention after a sharp share price move, with the stock closing at US$3.99. Investors are considering this in light of its recent returns and its ongoing Medicare Advantage focused business. See our latest analysis for Clover Health Investments. The latest 1 day share price return of 9.32% comes after a softer 7 day share price return of 4.55%. However, the 30 day share price return of 52.87% and 90 day share price return...

Olaplex Holdings (NasdaqGS:OLPX) has reached a court approved settlement in consolidated shareholder derivative litigation. The settlement requires corporate governance reforms and the withdrawal of related legal claims. Insurers are set to cover agreed legal fees as part of the settlement terms. The court has granted preliminary approval. The settlement marks a key moment for the company’s risk profile and oversight framework. Olaplex Holdings, known for its professional and consumer hair...

Viking Therapeutics (VKTX) is back in focus as investors track upcoming clinical catalysts for its obesity drug VK2735, including Phase 1 maintenance trial results in Q3 2026 that could influence expectations for the stock. See our latest analysis for Viking Therapeutics. Recent excitement around VK2735 has not prevented some cooling in the stock, with the share price down 16% year to date and the 90 day share price return also weaker, even as the 1 year and 5 year total shareholder returns...

Lamar Advertising recently reported that outdoor advertising demand remains healthy, with local markets solid and national advertisers returning, while digital billboards now make up nearly one-third of billboard billings and enhance its ability to flex ad inventory. Management’s decision to keep full-year AFFO guidance intact, coupled with the possibility of a dividend increase if trends persist, signals confidence in the cash-generating strength of its expanding digital footprint. Next,...

Wondering whether Gartner at around US$164.87 offers value or just more volatility? This article walks through what the current price really implies for you as a shareholder or potential buyer. The stock has risen 2.3% over the past week and 10.3% over the past month, yet remains down 30.4% year to date and has fallen 60.9% over the past year. This raises questions about how the market is reassessing its growth prospects and risk profile. Recent coverage has focused on how market sentiment...

Zymeworks recently reported positive updates across its oncology portfolio, including encouraging Phase 1 data for ZW191, advancement of its pan‑RAS ADC platform, and regulatory progress for zanatumab with a US PDUFA date set for August 25, 2026 and a supplemental BLA filing in China that triggered milestone payments from Jazz Pharmaceuticals and BeiGene. These clinical and regulatory advances, alongside a new US$125,000,000 share repurchase authorization and continued interest from global...

GE HealthCare Technologies (NasdaqGS:GEHC) received FDA clearance for its MIM Contour ProtégéAI+ 2.0 software. The AI enabled tool is designed to support more automated and precise radiation therapy planning for cancer patients. The clearance includes a Predetermined Change Control Plan that allows future AI features to be deployed more quickly. For investors watching GE HealthCare's oncology and imaging efforts, this update adds another piece to the broader medical technology story. The...

Zhihu (NYSE:ZH) reported Q1 2026 revenue of C¥651.6 million, with a basic EPS loss of C¥0.11 and a quarterly net income loss of C¥8.5 million. Over the trailing twelve months, revenue totaled C¥2.7 billion and the EPS loss stood at C¥2.42. The company has seen quarterly revenue move between C¥643.5 million and C¥859.2 million since Q4 2024, with basic EPS shifting from a profit of C¥1.01 in Q4 2024 to a loss of C¥2.66 in Q4 2025, followed by the latest quarter’s narrower loss. As a result,...

How W. R. Berkley’s recent performance looks in context W. R. Berkley (WRB) stock has delivered mixed returns recently, with a gain over the past week but declines over the past month and past 3 months, leaving the year to date performance in negative territory. Over a longer horizon, the stock shows a very different picture, with multi year total returns over the past 3 and 5 years that are well ahead of the recent shorter term pullback. This contrast may catch your eye if you track...

Earlier in 2026, Pacific Gas and Electric Company (PG&E) announced it had surpassed 1 million customers with solar systems connected to its grid, the highest number of any U.S. utility, reflecting large-scale adoption of customer-owned clean energy in California. The utility is also turning this vast base of rooftop solar and paired battery systems into virtual power plants through grid automation and advanced forecasting, aiming to strengthen reliability while integrating more renewable...

Viasat (VSAT) has quickly moved back into focus after two developments: a new role supplying satellite communications for NOAA’s Hurricane Hunter aircraft via Lockheed Martin, and quarterly results that missed revenue and earnings expectations. See our latest analysis for Viasat. Those mixed signals are showing up in the share price too, with the stock delivering a 30 day share price return of 11.22% and a year to date share price return of 93.81%. The 1 year total shareholder return is about...

Wondering if LPL Financial Holdings at around US$291.84 is priced for opportunity or risk? This article walks through what the current valuation really implies for you as a shareholder or potential buyer. The stock has risen about 9.8% over the past week, but is still down around 10.9% over the past month, 19.3% year to date, and 22.9% over the last year. This comes even after rising 47.3% over three years and 117.4% over five years. Recent coverage has focused on how wealth management...

Teva Pharmaceutical Industries (NYSE:TEVA) has launched AHZANTIVE, a biosimilar to Eylea, in Europe. The product targets retinal conditions treated with Eylea and expands Teva's presence in ophthalmology. The launch adds to Teva's biosimilars portfolio and supports its Pivot to Growth focus on complex biologic medicines. Teva enters this news cycle with its stock at $34.43 and very large multi year gains, including a 99.6% return over the past year and a 198.6% return over five years. Short...

IDEXX Laboratories stock: earnings beat and product expansion put diagnostics focus in the spotlight IDEXX Laboratories (IDXX) is back on investors’ radar after a first quarter earnings and revenue beat, an upgraded 2026 outlook, and a fresh expansion of its Fecal Dx parasite testing platform. See our latest analysis for IDEXX Laboratories. The recent earnings beat, upgraded 2026 outlook, and broader Fecal Dx parasite menu come after a period where the share price has eased, with the 90 day...

In recent days, Fortinet reported strong quarterly results, raised its full-year 2026 revenue guidance, and unveiled AI-driven offerings including FortiOS 8.0 and new FortiGate models, highlighting demand for its integrated security and networking platform. A key takeaway is Fortinet’s push to embed artificial intelligence across its security stack, which could further entrench its role in AI-focused security infrastructure. Now we’ll explore how Fortinet’s AI-driven product launch and...

Comfort Systems USA (NYSE:FIX) is seeing record quarterly results as it picks up more work on data centers tied to AI and high performance computing. The company is supplying specialized HVAC and mechanical systems for complex facilities that require advanced cooling solutions. Data center work helped drive 51% organic revenue growth in the latest quarter and is changing the mix of projects in its order book. For investors watching NYSE:FIX, the story now goes well beyond traditional...

Recent stock move and performance snapshot Commerce Bancshares (CBSH) stock was recently in focus after a modest daily gain of about 2%, prompting a closer look at how its longer term returns and fundamentals currently line up for investors. Over the past week, the stock returned about 0.8%, with moves of around 0.6% over the past month and 4.2% over the past 3 months. Year to date, the return is about 0.4%, while the 1 year total return shows a decline of roughly 9.8%. See our latest...

United Therapeutics recently reported that its TETON-1 phase 3 study of nebulized Tyvaso in idiopathic pulmonary fibrosis met its primary endpoint, preserving lung function and reducing clinical worsening events, and it entered a collaboration with Varda Space Industries to explore microgravity-based pharmaceutical processing for rare pulmonary diseases. Beyond reinforcing its pulmonary focus, this combination of positive late-stage IPF data and space-based manufacturing research highlights...

Sigma Lithium recently filed a year of third-party environmental monitoring data for its Brazilian operations, showing dust, noise, and vibration levels well below stringent national and ABNT/CONAMA standards across four neighbouring communities, directly contesting local court claims about environmental harm. The independently collected data not only supports the company’s low-impact mining credentials but also becomes a crucial evidentiary anchor in ongoing legal appeals in Minas Gerais,...

Compass stock snapshot Compass (COMP) stock has recently drawn investor interest, with the real estate platform reporting annual revenue of US$8.3b and net income of US$14.5m, alongside mixed share price moves over the past year. See our latest analysis for Compass. At a share price of US$7.88, Compass has seen a mixed pattern, with the 1 month share price return of 8.5% contrasting with a year to date share price decline of 25%, while the 3 year total shareholder return of 115% highlights...

UDR recently announced a share repurchase program authorizing buybacks of up to 25,000,000 shares, updated its 2026 financial guidance, and declared its 214th consecutive quarterly dividend on common stock. This combination of a large buyback authorization, refreshed earnings outlook, and uninterrupted dividend history highlights management’s current capital allocation priorities and confidence in the business. We’ll now examine how UDR’s sizable share repurchase authorization reshapes its...

Pershing Square (NYSE:PS) plans to begin releasing quarterly financial results starting in Q2 2026. The company will host live earnings webcasts that are open to the public. Management also intends to hold public Q&A sessions alongside the results webcasts. For you as an investor, this marks a clear shift in how Pershing Square communicates with its shareholders and broader audience. Regular results releases, webcasts, and Q&A sessions can provide more timely insight into how the company is...